Biopharmaceuticals are typically produced in cultured mammalian cells. The complex development and manufacturing method of these medicinal products results in their high pricing.
A Dutch biotech company has discovered and implemented genetic elements and developed highly cost-effective, production platforms for recombinant pharmaceutical proteins. Application of the technology increases production levels 2 to 3-fold compared to other systems commonly in use in the industry, resulting into improved efficiencies and lower production costs. Proof of value was demonstrated in different Chinese hamster ovary (CHO) cell types (e.g. adherent and suspension CHO-K1, CHO-DG44, CHO-GS) with different selection markers (e.g. blasticidin, puromycin, zeocin) for various proteins (e.g. monoclonal antibodies, biosimilars, difficult to express proteins).
Currently the Dutch SME focuses on two product classes: i. Biosimilars (generic biopharmaceuticals) and ii. difficult-to-express proteins (e.g. Fc-fusion proteins, bispecific proteins, membrane proteins, large multiple subunit proteins). For the latter, production inefficiencies currently prevent commercially viable levels and therefore inhibit their development. The technology is licensed to pharma companies.
The technology is patented, generally applicable (cell types, selection markers, expressed proteins), awarded and commercialized by licensing to pharmaceutical companies.
The SME is seeking collaboration with partners from companies and academia related to its expertise on producing proteins.
A research cooperation agreement is foreseen or a technical cooperation agreement, but also other types of collaboration can be discussed.
The cooperation types represents a broad range of R&D topics, such as the devolpment of mammalian cell-produced products and studying biopharmaceutical protein variants.